Lead Sponsor

AstraZeneca

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

•Healthy male and/or female subjects aged 18 to 55 years
•Able to inhale from the SPIRA nebuliser according to the provided instructions
•Females must have a negative pregnancy test at screening and on admission (Day 1) to the CPU, must not be lactating and must be of non-childbearing potential.
•Body mass index (BMI) between 18 and 30 kg/m2 inclusive and weighing at least 50 kg and no more than 100 kg inclusive.
•FEV1 \>80% of the predicted normal value.

•History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7624
•History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
•History or family history of muscle diseases
•Known or suspected history of drug abuse as judged by the Investigator
•Use of any prescribed or non-prescribed medication including antacids, analgesics other than paracetamol/acetaminophen, herbal remedies, vitamins (excluding routine vitamins but including megadose \[intake of 20 to 600 times the recommended daily dose\])

Related studies

NCT07665931 · Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Hyperinflation

NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07402551 · Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07509606 · Chronic Obstructive Pulmonary Disease (COPD), Whole Body Vibration

NCT07451977 · Chronic Respiratory Failure, Hypoxemia, and more

A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects